Purpose

This phase III trial compares the effect of text-based cessation intervention to a manual in helping rural cancer patients who smoke, quit. Text-based scheduled gradual reduction may reduce the frequency of cigarette use to zero and may be effective in quitting smoking.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Have a cancer diagnosis within the past 10 years, and can currently be receiving curative treatment - Not currently on hospice - Currently smokes >= 5 cigarettes daily - Lives in a nonmetro/rural county (defined as having a Rural Urban Continuum Code [RUCC] code of 4-9) - Patient interested in participating in a smoking cessation program, and not currently participating in a smoking cessation clinical trial - Not currently using any smoking cessation pharmacotherapy (e.g. nicotine replacement therapy, bupropion or varenicline), or currently participating in any cessation program - Patient has a cell phone or smart phone device with texting ability - In order to complete the mandatory patient-completed measures, participants must be able to speak and read English - Age >= 18 years - Participant must be willing to provide a urine sample.

Exclusion Criteria

  • Psychiatric illness which would prevent the patient from giving informed consent - Patients with impaired decision-making capacity are not eligible for this study.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Prevention
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Group I (SGR program, text messages)
Patients participate in schedule gradual reduction program over 8 weeks to reduce the frequency of cigarette use. Patients also receive cessation support messages via text messages for 12 weeks.
  • Behavioral: Smoking Cessation Intervention
    Participate in schedule gradual reduction program
  • Other: Health Promotion and Education
    Receive cessation support messages
  • Other: Questionnaire Administration
    Ancillary studies
Active Comparator
Group II (booklet)
Patients receive NCI's Clearing the Air booklet to help plan to gradually quit smoking.
  • Other: Informational Intervention
    Receive NCI's Clearing the Air booklet

Recruiting Locations

University of Kansas Health System Saint Francis Campus
Topeka, Kansas 66606
Contact:
Site Public Contact
785-295-8000

More Details

Status
Recruiting
Sponsor
Alliance for Clinical Trials in Oncology

Study Contact

Devon Noonan, PhD, MPH, FNP-BC
919-613-9130
devon.noonan@duke.edu

Detailed Description

PRIMARY OBJECTIVES: I. To evaluate the efficacy of an eight-week text-based scheduled gradual reduction (SGR) intervention (a personalized eight-week reduction schedule paired with National Cancer Institute's [NCI's] Smokefree.TXT) compared to a control intervention (NCI Clearing the Air Cessation Booklet) on biochemically-validated smoking cessation six-month post-quit date in rural cancer survivors. SECONDARY OBJECTIVE: I. Compare the efficacy of the eight-week text-based SGR intervention and a control intervention on Linear Analog Self-Assessment (LASA)-6 overall quality of life (QOL) at 30-days post-quit date and six-months post-quit date. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients participate in schedule gradual reduction program over 8 weeks to reduce the frequency of cigarette use. Patients also receive cessation support messages via text messages for 12 weeks. GROUP II: Patients receive NCI's Clearing the Air booklet to help plan to gradually quit smoking. After completion of study, patients are followed up at 6 months.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.